Kohima News Paper

Metachromatic Leukodystrophy Market Size, Epidemiology, Pipeline Therapies, Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Metachromatic Leukodystrophy Market Size, Epidemiology, Pipeline Therapies, Companies and Competitive Analysis by DelveInsight

April 18
21:45 2022
Metachromatic Leukodystrophy Market Size, Epidemiology, Pipeline Therapies, Companies and Competitive Analysis by DelveInsight
Metachromatic Leukodystrophy Market

(Albany, US) Metachromatic Leukodystrophy (MLD) is a rare inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. This condition is called metachromatic leukodystrophy because when viewed under a microscope, sulfatide accumulation in cells appears as granules that are colored differently than other cellular material (metachromatic).

DelveInsight’s “Metachromatic Leukodystrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Metachromatic Leukodystrophy (MLD), historical and forecasted epidemiology as well as the Metachromatic Leukodystrophy (MLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Metachromatic Leukodystrophy Market are:

  • According to the United Leukodystrophy Foundation, MLD is inherited in an autosomal recessive manner, and is most commonly caused by a mutation in a gene called Arylsulfatase A (ASA), also called sulfatide sulfatase. The protein produced by ASA is present in the lysosomal compartment of the cell.
  • The prognosis for MLD is poor. Most children within the infantile form die by age 5. Symptoms of the juvenile form progress with death occurring 10 to 20 years following onset. Those persons affected by the adult form typically die within 6 to 14 years following onset of symptoms.
  • As per the MalaCards Human Disease Database, MLD is inherited in an autosomal recessive manner with a prevalence of 1-9 per 100000 in Europe, United States and worldwide and the age of onset of different forms of MLD varies.
  • As per the Myriad Women’s Health, MLD is divided into three forms infantile (early-onset), juvenile (late-onset), and adult (late-onset) out of which infantile form is the most common with 50 to 60% of all the cases.
  • Through various secondary studies it can be concluded that MLD affects both males and females equally

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/metachromatic-leukodystrophy-mld-market

 

Scope of the Metachromatic Leukodystrophy Market Report:

  • The report covers the descriptive overview of Metachromatic Leukodystrophy (MLD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Metachromatic Leukodystrophy (MLD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Metachromatic Leukodystrophy (MLD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Metachromatic Leukodystrophy (MLD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Metachromatic Leukodystrophy (MLD) market

 

Some of Metachromatic Leukodystrophy Companies are:

  • Takeda
  • Talaris Therapeutics
  • Magenta Therapeutics
  • And Many Others

 

Metachromatic Leukodystrophy Drugs are:

  • TAK-611
  • FCR001
  • SHP611
  • MGTA-456
  • And Many Others

 

To know more about Metachromatic Leukodystrophy Pipeline therapies and companies, Click Here: https://www.delveinsight.com/sample-request/metachromatic-leukodystrophy-mld-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Metachromatic Leukodystrophy (MLD)

3. Competitive Intelligence Analysis for Metachromatic Leukodystrophy (MLD)

4. Metachromatic Leukodystrophy (MLD): Market Overview at a Glance

5. Metachromatic Leukodystrophy (MLD): Disease Background and Overview

6. Patient Journey

7. Metachromatic Leukodystrophy (MLD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Metachromatic Leukodystrophy (MLD) Unmet Needs

10. Key Endpoints of Metachromatic Leukodystrophy (MLD) Treatment

11. Metachromatic Leukodystrophy (MLD) Marketed Products

12. Metachromatic Leukodystrophy (MLD) Emerging Therapies

13. Metachromatic Leukodystrophy (MLD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Metachromatic Leukodystrophy (MLD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Others Reports:

Eczema Market

DelveInsight’s “Eczema Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Eczema, historical and forecasted epidemiology as well as the Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

About DelveInsight

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/metachromatic-leukodystrophy-mld-market

Categories